PDPN and breast carcinoma: These markers are highly upregulated in M-LECP recruited to clinical breast cancers as was determined by their expression in TLR4+/CD11b+ TAMs, which were also positive for lymphatic markers Lyve-1, podoplanin (Pdpn), or Vegfr-3 [10].